Whalesbook
Global brokerage Bernstein is optimistic about the Indian pharmaceutical sector, projecting growth to $195 billion by 2035. The report highlights potential in niche therapies and specialty businesses, favoring companies like Zydus Lifesciences, Lupin, and Sun Pharma while expressing caution on others like Mankind Pharma and Biocon.
What Happened
Global investment firm Bernstein has initiated coverage on the Indian pharmaceutical sector with a positive outlook. The brokerage expects the industry to grow from its current valuation of approximately $57 billion to $195 billion by 2035. This expansion is driven by a shift in focus from traditional generics to complex and specialty products, supported by increased R&D and AI-driven operational improvements.
Why This Matters For Investors
The Indian pharmaceutical industry is moving through a significant transition. For years, the sector relied heavily on high-volume, low-margin generic medicines for export. Bernstein notes that the next phase of growth is expected to come from higher-value segments, such as specialty generics, biosimilars, and innovative niche therapies. This shift could help companies improve their profit margins and reduce reliance on highly competitive generic drug markets in the U.S. and Europe.
The brokerage highlights six growth engines, including orphan drug designations, drug-device combinations, and metabolic therapies, which could add substantial value to the industry over the next decade. These segments often have fewer competitors and higher profit potential than standard generic medicines.
Where Brokerage Ratings Differ
Bernstein’s report categorizes several prominent Indian pharma stocks based on their ability to capitalize on these new growth opportunities. The firm has assigned an 'Outperform' rating to Zydus Lifesciences, Lupin, and Sun Pharma, suggesting these companies are better positioned to benefit from the shift toward specialty portfolios and innovation.
On the other hand, the brokerage is more cautious on other players. It has assigned an 'Underperform' rating to Mankind Pharma and Biocon, indicating that these companies may face more challenges or appear less attractive compared to their peers in this specific growth framework. Aurobindo Pharma has been given a 'Market-Perform' rating, suggesting the brokerage expects its performance to align with broader market trends.
Sector Risks and Realities
While the long-term growth story appears promising, investors must remain aware of systemic risks that continue to affect the pharmaceutical industry. The U.S. remains the largest export market for Indian drugmakers, and companies continue to face significant pricing pressure in that region as competitors enter the market and buyers consolidate.
Additionally, the sector is heavily regulated. Regulatory scrutiny from the U.S. Food and Drug Administration (FDA) and other international bodies can lead to inspection delays, import alerts, or production pauses, which directly impact revenue. Dependence on imported raw materials, particularly Active Pharmaceutical Ingredients (APIs) from overseas, also creates vulnerability to supply chain disruptions and price volatility. Finally, R&D in complex and specialty therapies is inherently risky; not every drug development project will succeed, and failure in late-stage trials can lead to cost overruns and lower-than-expected returns on capital.
What Investors Should Track
Going forward, the success of these companies will likely depend on their ability to execute complex R&D projects and maintain high regulatory compliance standards. Investors may want to monitor the progress of new drug applications (particularly 505(b)(2) filings in the U.S.), the resolution of any pending regulatory inspections at manufacturing facilities, and trends in operating margins. Companies that demonstrate the ability to maintain profitability while investing in new therapies and managing U.S. generic price erosion are likely to be the ones that sustain long-term growth.